但是，有些时候免疫系统的刹车或来自肿瘤的信号会削弱免疫反应，从而阻止TIL细胞杀伤肿瘤。于是科研人员对TIL本身进行了一些改进。从患者肿瘤中提取的一组已经识别出癌细胞上的许多靶标的TIL通过扩展 TIL数量，就可以为患者提供一支更大的免疫细胞大军，这些免疫细胞已经经过训练，可以识别和攻击患者的特定肿瘤。当身体为细胞做好准备时，患者通过输注接受 ...

Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines.

Rick Schneider is a family man — a husband and doting father to three girls. He’s also an outdoorsman who loves to bike, hike ...

肿瘤浸润调节性T细胞（Tumor-infiltrating regulatory T cells，TI-Treg cells）是肿瘤微环境中抑制抗肿瘤免疫并促进肿瘤进展的关键免疫细胞。尽管已有多种疗法旨在靶向TI-Treg细胞，然而大多数治疗效果不佳 ...

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint ...

Tumor inflitrating lymphocyte therapies are a promising type of cellular immunotherapy used to treat a broad range of solid ...

As part of an effort to increase its cell therapy manufacturing, Iovance Biotherapeutics is planning to add hundreds of new ...

Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a platform company focused on cell and gene therapy applications, and Royal Perth Hospital announced a ...

SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...

(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an ...